Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (179)
ARTG (99)
Prescription medicine registration (27)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)
Prescription medicine evaluation (1)

Date

2026 (12)
2025 (32)
2024 (120)
2023 (13)
2022 (13)
2021 (57)
2020 (23)
2019 (8)
2018 (5)
2017 (6)
2016 (18)
2015 (2)
2012 (1)
2011 (4)
2006 (3)
1995 (2)

Search

Sponsor content

319 result(s) found, displaying 271 to 280

TEVAPEZIL donepezil hydrochloride (as monohydrate) 10 mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 2.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 7.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EVEROLIMUS-TEVA everolimus 7.5 mg tablet blister pack (277286)

20 April 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EVEROLIMUS-TEVA everolimus 7.5 mg tablet blister pack.
EVEROLIMUS-TEVA everolimus 10 mg tablet blister pack (277287)

20 April 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EVEROLIMUS-TEVA everolimus 10 mg tablet blister pack.
EVEROLIMUS-TEVA everolimus 2.5 mg tablet blister pack (277284)

20 April 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EVEROLIMUS-TEVA everolimus 2.5 mg tablet blister pack.
EVEROLIMUS-TEVA everolimus 5 mg tablet blister pack (277285)

20 April 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for EVEROLIMUS-TEVA everolimus 5 mg tablet blister pack.
AusPAR: Fremanezumab

24 January 2020

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Fremanezumab
Ajovy

13 December 2019

Prescription medicine decision summary

Australian prescription medicine decision summary

Pages

First page
Previous page
…
Page 24
Page 25
Page 26
Page 27
Current page 28
Page 29
Page 30
Page 31
Page 32
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.